ACADIA Pharmaceuticals Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-08-27$26.57 RISE2025-10-13$20.06 PEAK2025-12-22$28.06 117d | -24.5% 47d | Missed | Missed | — | — | +39.9% 70d | Missed |
DROP2025-08-27$26.57 RISE2025-10-10$20.06 PEAK2025-12-22$28.06 117d | -24.5% 44d | Missed | Missed | — | — | +39.9% 73d | Missed |
DROP2025-02-20$20.29 RISE2025-04-08$14.10 PEAK2025-06-18$22.95 118d | -30.5% 47d | Missed | Missed | — | — | +62.8% 71d | Missed |
DROP2024-07-26$19.14 RISE2024-10-23$14.29 PEAK2024-12-09$18.76 136d | -25.3% 89d | Missed | Missed | — | — | +31.3% 47d | Missed |
DROP2024-01-23$28.15 RISE2024-05-29$14.62 PEAK2024-07-26$19.14 185d | -48.1% 127d | Missed | Missed | — | — | +30.9% 58d | Missed |
DROP2023-08-21$30.32 RISE2023-12-08$20.98 PEAK2023-12-27$31.77 128d | -30.8% 109d | Missed | Missed | — | — | +51.4% 19d | Missed |
DROP2023-07-17$33.47 RISE2023-10-03$20.78 PEAK2023-12-27$31.77 163d | -37.9% 78d | Missed | Missed | — | — | +52.9% 85d | Missed |
DROP2022-10-06$18.63 RISE2022-12-09$14.49 PEAK2023-03-01$20.92 146d | -22.2% 64d | Missed | Missed | — | — | +44.4% 82d | Missed |
DROP2022-10-06$18.63 RISE2022-11-07$14.49 PEAK2023-02-02$19.91 119d | -22.2% 32d | Missed | Missed | — | — | +37.4% 87d | Missed |
DROP2022-04-06$27.22 RISE2022-08-01$14.11 PEAK2022-10-06$18.63 183d | -48.2% 117d | Missed | Missed | — | — | +32.0% 66d | Missed |
DROP2022-02-16$27.50 RISE2022-06-21$13.01 PEAK2022-09-15$18.27 211d | -52.7% 125d | Missed | Missed | — | — | +40.4% 86d | Missed |
DROP2022-02-16$27.50 RISE2022-05-11$15.29 PEAK2022-06-16$19.51 120d | -44.4% 84d | Missed | Missed | — | — | +27.6% 36d | Missed |
DROP2022-02-16$27.50 RISE2022-03-14$22.27 PEAK2022-04-06$27.22 49d | -19.0% 26d | Missed | Missed | — | — | +22.2% 23d | Missed |
DROP2021-12-20$27.09 RISE2022-01-18$20.94 PEAK2022-02-16$27.50 58d | -22.7% 29d | Missed | Missed | — | — | +31.3% 29d | Missed |
DROP2021-07-29$22.29 RISE2021-12-03$18.79 PEAK2022-02-16$27.50 202d | -15.7% 127d | Missed | Missed | — | — | +46.4% 75d | Missed |
1–15 / 19 1 / 2 | |||||||
Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide updates on commercial trends for NUPLAZID and DAYBUE, and discuss selected pipeline and business develo
We didn't see ACADIA Pharmaceuticals Inc.'s ( NASDAQ:ACAD ) stock surge when it reported robust earnings recently. We...
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders, according to comments at the Bank of America Global Healthcare Conference. Chief Executive Officer Cat
ACADIA Pharmaceuticals Inc. (ACAD) Bank of America Global Healthcare Conference 2026 May 12, 2026 7:20 PM EDTCompany ParticipantsCatherine Owen Adams - CEO...
Presenter SpeechTazeen Ahmad Good afternoon. Welcome back to Bank of America Healthcare Conference. I'm Tazeen Ahmad. I am one of bio analysts here at the bank. It's my pleasure to have our next...
It's shaping up to be a tough period for ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ), which a week ago released some...
In early May 2026, ACADIA Pharmaceuticals Inc. reported first-quarter revenue of US$268.06 million with net income of US$3.64 million, while also disclosing a negative regulatory opinion on trofinetide in Europe and reaffirming its full-year outlook. At the same time, the company announced the planned retirement of its Head of Research and Development, Elizabeth H.Z. Thompson, Ph.D., who will remain as a consultant through at least the end of 2026 to support key late-stage clinical...
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $33 to $32.
Acadia's first-quarter earnings and revenues miss estimates despite 10% sales growth, driven by Nuplazid and Daybue demand.
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call May 6, 2026 4:30 PM EDTCompany ParticipantsAlbert Kildani - Senior Vice President of Investor...
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported first-quarter 2026 total revenue of $268 million, and executives said the company is maintaining its full-year outlook as it advances a pipeline led by remlifanserin in Alzheimer’s disease psychosis and trofinetide in Japan. Chief Executive Officer Cath
Albert Kildani: Good afternoon, and thank you for joining us on today's call to discuss ACADIA Pharmaceuticals Inc.'s First Quarter 2026 Financial Results. Joining me on the call today from ACADIA Pharmaceuticals Inc. are Catherine Owen Adams, our Chief Executive Officer, who will provide opening remarks; followed by Thomas Garner, our Chief Commercial Officer, who will discuss our commercial brands, DAYBUE and NUPLAZID. Also joining us are Elizabeth Thompson, PhD, Executive Vice President, Head of Research and Development, who will provide an update on our pipeline programs; and Mark C. Schneyer, our Chief Financial Officer, who will review the financial highlights.
2026-05-06. The following slide deck was published by ACADIA Pharmaceuticals Inc.
Acadia (ACAD) delivered earnings and revenue surprises of -54.23% and -5.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Presentation Operator MessageOperator Ladies and gentlemen, thank you for standing by. My name is Krista, and I will be your conference operator today. At this time, I would like to welcome
Acadia Pharmaceuticals missed Q1 2026 earnings estimates, with revenue of $268M and EPS of $0.02 below forecasts, causing a 4.3% after-hours stock drop.
SAN DIEGO — SAN DIEGO — Acadia Pharmaceuticals Inc. on Wednesday reported first-quarter earnings of $3.6 million. On a per-share basis, the San Diego-based company said it had profit of 2...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ACAD | -1.32% | -5.04% | -18.91% | +0.42% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -4.29% | +0.67% | -15.46% | -12.27% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 8.33M | $185.49M | 0.01% | Added+5.3% | 2026-03-31 |
| Citadel | multi-strat | 2.58M | $57.38M | 0.07% | Trimmed-23.7% | 2026-03-31 |
| RenTech | quant | 1.72M | $38.38M | 0.06% | Added+12.5% | 2026-03-31 |
| TwoSigma | quant | 775.1K | $17.25M | 0.01% | Trimmed-30.7% | 2026-03-31 |
| DEShaw | quant | 729.8K | $16.25M | 0.01% | Trimmed-28.9% | 2026-03-31 |
| FidelityFMR | fundamental | 350.3K | $7.80M | 0.00% | Trimmed-51.8% | 2026-03-31 |
| Bridgewater | macro | 141.8K | $3.16M | 0.01% | Added+2.6% | 2026-03-31 |
| Wellington | fundamental | 50.0K | $1.11M | 0.00% | Trimmed-6.2% | 2026-03-31 |
| TRowePrice | fundamental | 634.7K | $14.13K | 0.00% | Added+3.2% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-27 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | S Open-market sale | 5,401 | $21.18 | −$114.4K |
| 2026-05-05 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | M Option exercise(deriv) | 6,815 | — | +$0 |
| 2026-05-05 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | S Open-market sale | 3,506 | $21.79 | −$76.4K |
| 2026-05-05 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | M Option exercise | 6,815 | — | — |
| 2026-05-05 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | M Option exercise(deriv) | 2,596 | — | +$0 |
| 2026-05-05 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | S Open-market sale | 1,332 | $21.79 | −$29.0K |
| 2026-05-05 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | M Option exercise | 2,596 | — | — |
| 2026-04-07 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | M Option exercise(deriv) | 2,010 | — | +$0 |
| 2026-04-07 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | S Open-market sale | 1,030 | $22.20 | −$22.9K |
| 2026-04-07 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | M Option exercise | 2,010 | — | — |
| 2026-04-07 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | M Option exercise(deriv) | 5,276 | — | +$0 |
| 2026-04-07 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | S Open-market sale | 2,709 | $22.20 | −$60.1K |
| 2026-04-07 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | M Option exercise | 5,276 | — | — |
| 2026-03-26 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | M Option exercise(deriv) | 6,178 | — | +$0 |
| 2026-03-26 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | M Option exercise(deriv) | 8,138 | — | +$0 |
| 2026-03-26 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | S Open-market sale | 37 | $21.72 | −$804 |
| 2026-03-26 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | S Open-market sale | 3,171 | $21.65 | −$68.7K |
| 2026-03-26 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | M Option exercise | 6,178 | — | — |
| 2026-03-26 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | S Open-market sale | 4,177 | $21.47 | −$89.7K |
| 2026-03-26 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | M Option exercise | 8,138 | — | — |
| 2026-03-26 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | M Option exercise(deriv) | 2,142 | — | +$0 |
| 2026-03-26 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | M Option exercise(deriv) | 1,627 | — | +$0 |
| 2026-03-26 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | S Open-market sale | 12 | $21.73 | −$261 |
| 2026-03-26 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | S Open-market sale | 1,097 | $21.65 | −$23.8K |
| 2026-03-26 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | M Option exercise | 2,142 | — | — |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | 0.04 | — | — |
| 2026-05-06 | 0.08 | 0.02 | -75.22% |
| 2026-02-25 | 0.14 | 0.14 | -4.19% |
| 2025-11-05 | 0.15 | 0.42 | +189.02% |
| 2025-08-06 | 0.14 | 0.16 | +15.27% |
| 2025-05-07 | 0.11 | 0.11 | +4.48% |
| 2025-02-26 | 0.22 | 0.86 | +292.64% |
| 2024-11-06 | 0.14 | 0.20 | +41.23% |
| 2024-08-06 | 0.18 | 0.20 | +13.90% |
| 2024-05-08 | 0.06 | 0.10 | +66.97% |
| 2024-02-27 | 0.31 | 0.28 | -9.51% |
| 2023-11-02 | -0.42 | -0.40 | +5.41% |
| 2023-08-02 | -0.12 | 0.01 | +108.64% |
| 2023-05-08 | -0.21 | -0.27 | -28.72% |
| 2023-02-27 | -0.25 | -0.26 | -3.84% |
| 2022-11-02 | -0.20 | -0.17 | +13.02% |